The first issue of Psychedelia, a new magazine dedicated exclusively to the emerging legal world of psychedelics, will be reaching subscribers by early November.
The quarterly publication will explore the latest in medical research, cutting-edge science and all aspects of the exploding business sector. It will examine the ever-changing realm of drug policy and efforts to bring psychedelic therapies into the mainstream. It will feature in-depth articles and interviews with leaders of the movement, as well as trailblazers in business, innovators in science and the rebels of traditional medicine and education.
And although Psychedelia only supports the safe, legal use of psychedelics, it will look into the future in which alternative therapies and plant-based medicine are welcomed and accepted throughout the world.
In November 2020, Oregon became the first state in the country to legalize psylocibin and decriminalize all other drugs. Cities in California, Colorado, Massachusetts and Michigan have decriminalized natural psychedelics, while numerous countries, including the Bahamas, Jamaica, Nepal and Netherlands have legalized psilocybin.
Psychedelia is a collaboration of four leading companies in the cannabis and psychedelics arenas, covering a wide swath of business and culture: Psychedelics Go, Marijuana Venture, Microdose, and Zuber Lawler.
While most psychedelic compounds remain illegal at the federal level in the United States, the laws are evolving quickly and numerous clinical trials are already underway to research the medical efficacy of various psychedelics to treat ailments ranging from post-traumatic stress disorder, depression, anxiety and substance use disorder.
To subscribe to Psychedelia, visit www.Psychedelia.Live.